| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 66.55 | 11.2% |
| Total Income | 66.55 | 11.2% |
| Expenditure | 48.78 | 3.2% |
| PBT | 19.67 | 38.1% |
| Net Profit | 15.68 | 42.4% |
| OPM | 26.71% | 5.62pp |
| NPM | 23.56% | 5.17pp |
| EPS | 0.69 | 40.8% |
LeMaitre Vascular Reports Q1 2026 Sales $66.6mm, Up 11% YoY
06 May 2026 · 6 May, 2:10 am
Summary
LeMaitre Vascular, Inc. reported Q1 2026 financial results, with sales reaching $66.6 million, an 11% increase compared to Q1 2025. Gross margin improved to 72.7%, up 350 bps, and operating income increased by 41% to $17.8 million. EPS grew by 42% to $0.68. The company provided guidance for Q2 2026 and full-year 2026, projecting sales growth of 11% and 12%, respectively.
Key Highlights
- 1
LeMaitre Vascular reported Q1 2026 sales of $66.6 million, an increase of 11% compared to Q1 2025.
- 2
The company's gross margin for Q1 2026 was 72.7%, representing an increase of 350 bps.
- 3
Operating income for Q1 2026 reached $17.8 million, reflecting a 41% increase year-over-year.
- 4
Earnings per share (EPS) for Q1 2026 was $0.68, a 42% increase compared to the prior year.
- 5
Cash increased sequentially by $8.1 million to $367.2 million.
- 6
Artegraft sales grew by 36% worldwide in Q1, driven by its international launch.
- 7
The company announced a quarterly dividend of $0.25 per share.
Management Comments
George LeMaitre
Higher ASPs, geographic expansion and disciplined spending produced 11% sales growth and 42% EPS growth in Q1. Full year 2026 shows op. leverage too - increased guidance implies 12% sales growth and 26% (adjusted) EPS growth.”
Informational and educational content only. Not investment advice.